Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Landogrozumab, an antibody targeting MSTN.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Labetuzumab, an antibody targeting CEACAM5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Domagrozumab, an antibody targeting MSTN.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Carotuximab, an antibody targeting ENG.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bleselumab, an antibody targeting TNFRSF5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ascrinvacumab, an antibody targeting ACVRL1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vonlerolizumab, an antibody targeting OX40.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Remtolumab, an antibody targeting IL-17A × TNF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Porgaviximab, an antibody targeting Zaire Ebolavirus Glycoprotein.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Olendalizumab, an antibody targeting C5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lutikizumab, an antibody targeting IL1A × IL1B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lacnotuzumab, an antibody targeting CSF1.